The measurement of patient experience is a science. Collecting valid patient experience data (PED) helps support regulatory approvals and reimbursement, and promotes market access and product differentiation. But the first challenge in PED is determining what data to capture—and the right way to capture that data—in order to draw valuable insights directly from the patient while complying with regulatory guidelines.
IQVIA’s Patient Centered Solutions (PCS) team is a global leader in the science of measuring meaningful patient outcomes. PCS applies scientific discipline to accurately capture the patient experience and incorporate PED into trial endpoints primarily through the use of standardized questionnaires or instruments known as clinical outcome assessments (COAs).
By enriching study processes with patient-centricity, we help leading biopharma companies define smarter endpoints, gain market access and earn distinction in crowded categories.
Only IQVIA offers a fully integrated, global PED solution—combining strategy and outcomes research, instrument licensing and development, expert COA design and implementation services, and Rater Services (formerly Cronos Clinical Consulting). We partner with you from start to finish to simplify handoffs, embed regulatory expertise, and enable faster, more precise execution.
The PCS team is relentlessly focused on advancing science and technologies for capturing, benchmarking and interpreting actionable data from the patient’s perspective. We support quality PED collection and COA strategy from clinical implementation to data analysis, interpretation and dissemination.
IQVIA leads early-stage PED strategy, defining what to measure and how, applying scientific and therapeutic expertise, especially in CNS and oncology conditions. We develop study design, outcomes research, real-world evidence (RWE) generation, COA implementation, regulatory endpoint consulting and stakeholder alignment to prioritize the right measures for approvals and reimbursement. As the leader in PED services, the IQVIA PCS team guides the industry in strategically identifying what matters to most to patients.
Our book Patient-centricity in the Biopharmaceutical Industry: Are We Nearly There Yet? gathers insights on patient-centric intervention development from a diverse group of more than 30 experts.
Using Patient Experience Data to Evaluate Medical Interventions collects thoughtful perspectives from physicians, medical researchers, social scientists and strategy consultants.
Defining and Analyzing Patient-centric Endpoints Based on COAs and Digital Technologies promotes the basics of COA implementation and analysis in the pharma industry.
COAs can be:
Managing COA instrument licensing can be complex, as requirements vary by instrument copyright holder and intended use. Licensing may involve identifying the correct owner, securing permissions for use, addressing translation needs, and ensuring compliance with study and regulatory requirements. In some cases, licensing can also include adapting or digitizing an existing instrument.
IQVIA can support this process by helping identify appropriate instruments, managing licensing discussions with copyright holders, and coordinating required permissions, translations, or adaptations to reduce administrative burden and help ensure the instrument is used correctly and compliantly.
.svg){kind=icon}
